NasdaqGM:ALTBiotechs
Altimmune (ALT) Valuation Check After Pemvidutide’s FDA Breakthrough Therapy Designation
FDA Breakthrough designation puts pemvidutide in focus
Altimmune (ALT) has drawn fresh attention after the FDA granted Breakthrough Therapy Designation to its lead candidate pemvidutide for MASH, based on mid stage trial data showing significant disease resolution.
See our latest analysis for Altimmune.
The FDA Breakthrough Therapy news has arrived during a period of building momentum for Altimmune, with the 7 day share price return of 33.49% and year to date share price return of 61.25%...